Aeterna Zentaris Announces FDA Approval of Macrilen™ (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
Aeterna Zentaris Inc. (AEZS)
Last aeterna zentaris inc. earnings: 11/7 06:28 pm
Check Earnings Report
US:NASDAQ Investor Relations:
zentaris.com
Company Research
Source: GlobeNewswire
CHARLESTON, S.C., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD). The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe. “Aeterna Zentaris is proud of our commitment to patients with suspected AGHD and to the endocrinology community who we are confident will welcome an easier safe and effective oral diagnostic tool,” said Michael V. Ward, Chief Executive Officer, Aeterna Zentaris. “In the absence of an FDA-approved diagnostic test for AGHD, Macrilen™ fills an important gap and addresses a medical need for a con
Show less
Read more
Impact Snapshot
Event Time:
AEZS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEZS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEZS alerts
High impacting Aeterna Zentaris Inc. news events
Weekly update
A roundup of the hottest topics
AEZS
News
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyGlobeNewswire
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsGlobeNewswire
- Aeterna Zentaris Inc. (NASDAQ: AEZS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
AEZS
Sec Filings
- 3/27/24 - Form 20-F
- 3/27/24 - Form 6-K
- 3/27/24 - Form 6-K
- AEZS's page on the SEC website